

PERSONAL INFORMATION

Alessandra Carobbio

SCIENTIFIC PROFILE
SUMMARY

Master's degree in Biostatistics, active in the field of scientific research for over 15 years, documented by 115 indexed publications for a total H-index of 57 (source: Google Scholar). National scientific qualification as associate professor for concurrency area 06/M1 (GSD 24: 06-MEDS-24) obtained in April 2021.

Currently associate professor of medical statistics at the Department of Medical and Surgical, Maternal, Infant and Adult Sciences, University of Modena-Reggio Emilia. Extensive knowledge of clinical trial regulatory regulations gained from three years' experience as a member of two independent Ethics Committees.

Several collaborations with hospital health management for the development of strategic corporate projects.

Undergraduate teaching in several Graduate Courses, in Italian and English.

Responsibility for data analysis and coordination of Italian, European and international multicenter studies according to GCP standards.

Experience as a biostatistician on staff at the Phase I Unit and member of the CTQC.

Main area of application in oncohematology, but experience in research collaborations in multiple areas: pediatric, neurological, surgical-transplant, infectious disease, cardiology, internist.

Application and development of advanced statistical analysis methods.

Main software of use: STATA, R, SAS

WORK EXPERIENCE

2023 - now

Associate Professor of Medical Statistic

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO-EMILIA

Dipartimento di Scienze Mediche e Chirurgiche, Materno-Infantili e dell'Adulto

2013 – 2023

Senior biostatistician

FROM - ONDAZIONE PER LA RICERCA OSPEDALE DI BERGAMO ETS

ASST "PAPA GIOVANNI XXIII" – Piazza OMS,1 – 24127 Bergamo

2010 – 2013

Expert in Biostatistics at Ethics Committee (EC) according to the Ministerial Decree of 12/05/2006, in staff to the Scientific Secretariat.

1. ETHIC COMMITTEE - AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" and ASST "PAPA GIOVANNI XXIII" Bergamo
2. ETHIC COMMITTEE - OSPEDALI SAN GIUSEPPE DI MILANO E SACRA FAMIGLIA DI ERBA (C.E.MI.ER)

2007 – 2010

FIRC - Fondazione Italiana per la Ricerca sul Cancro-AIRC Fellowship

Three-year Cancer Research Fellowship for the project "The use of C-statistics for assessing prognostic value of new biomarkers in the risk stratification of patients with myeloproliferative disorders"

AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" – Unit of Hematology.

EDUCATION AND TRAINING

2021-2032

NATIONAL SCIENTIFIC QUALIFICATION AS ASSOCIATE PROFESSOR (GSD 24: 06-MEDS-24: MEDICAL STATISTIC)

- Habilitated 26.04.2021

2003 - 2006

BIOSTATISTICA E STATISTICA SPERIMENTALE (class: 92 / S)

Università degli Studi di Milano Bicocca – Facoltà di Scienze Statistiche

▪ Master degree, 110 e lode / 110. Defense date: 21/04/2006

2000 - 2003

SCIENZE STATISTICHE, DEMOGRAFICHE E SOCIALI (class: 37)

Università degli Studi di Milano Bicocca – Facoltà di Scienze Statistiche

▪ Bachelor degree, 110 e lode / 110. Defense date: 7/11/2003

TEACHING ACTIVITIES

UNIVERSITY LECTURING

a.y. 2010/11 (16 hours)

a.y. 2011/12 (16 hours)

a.y. 2022/23 (16 hours)

Module title “Statistica medica” of the course “Igiene, medicina del lavoro e statistica medica”

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA - FACOLTÀ DI MEDICINA E CHIRURGIA

Corso di Laurea in Infermieristica

Corso di Laurea in Ostetricia

a.y. 2010/11 (10 hours)

a.y. 2011/12 (10 hours)

a.y. 2012/13 (10 hours)

a.y. 2013/14 (10 hours)

a.y. 2014/15 (10 hours)

a.y. 2015/16 (10 hours)

Module title “Elementi di Statistica, metodi, strumenti indicatori”

UNIVERSITÀ DEGLI STUDI DI BERGAMO - COLLEGIO IPASVI BERGAMO

Master universitario di I livello “Management per le funzioni di coordinamento per le professioni sanitarie infermieristiche e ostetriche”

a.y. 2019/20 (10 hours)

a.y. 2020/21 (10 hours)

a.y. 2021/22 (10 hours)

a.y. 2022/23 (10 hours)

Module title “Applications of medical statistics” of the elective course “Turning clinical experience into research projects”

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA - SCHOOL OF MEDICINE AND SURGERY

a.y. 2021/22 (4 hours)

a.y. 2022/23 (4 hours)

a.y. 2023/24 (4 hours)

a.y. 2024/25 (4 hours)

a.y. 2025/26 (4 hours)

Module title “Statistical distribution functions”

UNIVERSITÀ DEGLI STUDI DI MILANO-BICOCCA - SCHOOL OF MEDICINE AND SURGERY

Master universitario di II livello “MEDAL (Methods and Data Analysis) in Biomedical Research”

a.y. 2022/23 (8 hours)

a.y. 2023/24 (6 hours)

Module title “Health technology assessment”

UNIVERSITÀ DEGLI STUDI DI BERGAMO

Corso di Laurea in Ingegneria per le Tecnologie della Salute

a.y. 2023/24 (6 hours)

Module title “Medical statistics”

UNIVERSITÀ DEGLI STUDI DI BERGAMO

Master Universitario di II livello “INTERNATIONAL MASTER OF CARDIOLOGY AND TECHNIQUES APPLIED TO CARDIAC SURGERY”

a.y. 2023/24 (30 hours)

Module title “Statistica medica”

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Scuola di specializzazione in Farmacologia Clinica

2024 edition (14 hours)

2025 edition (14 hours)

2026 edition (14 hours)

Module title “Regressione lineare semplice e multipla”

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Corso di perfezionamento “Statistica applicata ai quesiti clinici”

a.y. 2024/25 (40 hours)
a.y. 2024/25 (30 hours)

Module title "Statistica medica"

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Corso di Laurea in Fisioterapia, Logopedia, Terapia Occupazionale e Tecnica di riabilitazione psichiatrica

a.y. 2024/25 (24 hours)
a.y. 2025/26 (24 hours)

Module title "Statistica medica"

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Corso di Laurea in Farmacia

a.y. 2025/26 (32 hours)

Module title "Metodologie per la ricerca"

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Corso di Laurea in Farmacia

a.y. 2024/25 (20 hours)
a.y. 2025/26 (20 hours)

Module title "Statistica medica"

UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

Corso di Laurea Magistrale in Scienze infermieristiche e ostetriche

INSTITUTIONAL ACADEMIC POSITIONS

21/02/2024 - now

Member of **Consiglio Scientifico (CSB) della Biblioteca Univeristaria Medica 2023/2026**

19/11/2024 - now

Member of **Commissione ricerca del Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto**

16/10/2025 - now

Member of **Comitato Etico per la Ricerca dell'Università degli Studi di Modena e Reggio Emilia 2025/2029**

27/03/2026 - now

Member of **Osservatorio della Ricerca dell'Università degli Studi di Modena e Reggio Emilia 2026/2029.**

RESEARCH PROJECTS

01/01/2012 - 31/12/2017

Biostatistic of the **International Working Group for MPN Research and Treatment (IWG-MRT)** working on these project:

1. **Review of WHO diagnostic criteria for polycythemia vera and prefibrotic myelofibrosis** (Swerdlow SH, et al. *WHO classification of Tumours of Haematopoietic and Lymphoid Tissues*. 4th edn. Lyon, France: International Agency for Research on Cancer; 2017)
2. **Implementation and validation of a new thrombotic risk score (IPSET-thrombosis) in essential thrombocythemia**, included in the guideline: *NCCN Guidelines for Patients Myeloproliferative Neoplasms, Version: 2.2021*

01/01/2013 - 15/12/2023

Biostatistician involved in the statistical analysis of the following international collaborative projects:

1. CVT-MPN study (*Cerebral Vein Thrombosis in Myeloproliferative Neoplasms Study*)
2. AVK-DOACs MPN survey (*Survey of venous thrombosis of patients with Ph-negative Myeloproliferative Neoplasms*)
3. PRISM study (*Preventing Recurrent Ischemic Stroke in Myeloproliferative neoplasms study*)
4. RT-pre-PMF study (*Risk of Thrombosis in prefibrotic Primary Myelofibrosis*)
5. MPN-K study (*Secondary Cancers in Myeloproliferative Neoplasms study*)
6. MPN-DOACs study (*Use of Direct Oral Anticoagulants (DOACs) in patients with Ph-negative Myeloproliferative Neoplasms study*)
8. MPN-COVID study (*Myeloproliferative neoplasms (MPN) and COVID-19 study*)
9. ERNEST 2.0 study (*European Registry for Myeloproliferative Neoplasms (MPNs)- Update of ERNEST study*)
10. ROPEG-PV study (*Observational study on the use of ropeginterferon alfa-2b in polycythemia vera*)

01/01/2014 - 31/12/2015

Member of the Methodology Committee of "**CUBE guidelines for hematology**" sponsored by **Società Italiana di Ematologia (SIE)**

01/01/2017 - 15/12/2023

Leading biostatistician and Steering Committee member of the **RCT Fase II study "The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (Low-PV)"** (ClinicalTrials.gov identifier: NCT03003325)

15/01/2020 – 15/12/2023

Participation in the European project **HARMONY** (Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology) - Bid Data Platform for the collection and harmonization of data from clinical trials in the field of hematology

15/12/2019 - 15/12/2023

Statistician at the Phase I Unit of ASST Papa Giovanni XXIII in Bergamo according to Determina AIFA n. 809/2015

06/02/2023 - 15/12/2023

Member of the **Clinical Trial Quality Team (CTQT)** at the **Phase I Unit** of ASST Papa Giovanni XXIII in Bergamo according to Determina AIFA n. 809/2015

PUBLIC HEALTH PROJECTS

21/12/2010 - 31/12/2013

Member of the **Gruppo Operativo Intensità di Cure (GOIC)**, established by the Management of the AO "Ospedali Riuniti di Bergamo" by resolution No.0052716/2010 to comply with the need to have a permanent reference group at the corporate level with functions of study, design, implementation and monitoring of an organization based on intensity of care..

01/01/2019 - 31/12/2021

Collaborator in the **ALFRED (Automatic process pLanning support software For InteRnal hospital and Ethic comitee Documental organization)** project, an IT platform to support the management and tracking of clinical trials submitted for approval by the EC and the economic feasibility study according to the new European Clinical Trials Regulation No. 536/2014.

HONORS AND AWARDS

2007

Winner of "Premio per la Statistica Medica e l'Epidemiologia Clinica"

Società Italiana di Statistica Medica ed Epidemiologia Clinica, SISMEC

- Call for application for the 5 best undergraduate, doctoral, postgraduate and master theses on topics in statistical and epidemiological methodology applied to clinical and public health problems.

2014

Winner of "Premio Guido Berlucci Giovani Ricercatori"

Fondazione Guido Berlucci

- Call for applications for Italian researchers under the age of 40 who have published relevant research in the field of oncology in journals indexed 1st or 2nd name.

2016 Winner of "Fellowship Program – Area oncoematologica" GILEAD

- Call for proposals designed to support the design and implementation of projects of a scientific or social-health nature aimed at furthering public health goals and improving disease outcomes and quality of life for patients with HIV, hepatitis C, oncohematological diseases, and invasive fungal infections.

PEER REVIEWER FOR MEDICAL AND SCIENTIFIC JOURNALS

- | | |
|------------|---|
| 2020 – now | ▪ Annals of Hematology - Springer Nature (ISSN: 0939-5555) |
| 2021 – now | ▪ Blood Advances (ISSN: 2473-9537) |
| | ▪ Blood Cancer Journal (ISSN: 2044-5385) |
| 2022 – now | ▪ Haematologica (ISSN: 0390-6078) |
| | ▪ Future Oncology (ISSN: 1479-6694) |
| | ▪ Thrombosis Research (ISSN: 1879-2472) |
| 2023 - now | ▪ Blood (ISSN: 0006-4971) |
| | ▪ Nature Medicine (ISSN: 1078-8956) |
| | ▪ Transfusion and Apheresis Science (ISSN: 1473-0502) |

POSTER/ORAL/WORKSHOP COMMUNICATIONS WITHIN CONGRESSES

Participation in several meetings of scientific societies (ASH, EHA, ELN, SISMEC, AFI) , with oral and poster presentations. The following oral presentations are noted:

- | | |
|------------|---|
| 10/12/2007 | Oral presentation of the abstract " Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia " at the 49th American Society of Hematology (ASH) Meeting in Atlanta, USA |
| 11/11/2019 | Speaker of the presentation " Improving the grading system of the risk of thrombosis in PV " at the International Meeting Consensus statement by the European LeukemiaNet (ELN) on "Unmet clinical needs of management of thrombosis in Myeloproliferative Neoplasms," sponsored by the Menarini Foundation |
| 20/09/2024 | Oral presentation of the abstract " The role of polypharmacy in people living with HIV " at the Società Italiana di Statistica medica e Epidemiologia clinica (SISMEC) congress in Modena, Italy |

PUBLICATION

- Author and co-author of **115 scientific publications** in international peer-reviewed journals (see annex). **H-index: 57; i10-index: 100** (source: Google Scholar). Last updated: 08/07/2026


ANNEXES

- Comprehensive list of publications (updated July 8, 2026).

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dal Regolamento UE n. 679/2016 – GDPR General Data Protection Regulation, D.Lgs 196/2003 modificato da D.Lgs 101/2018.

Modena, July 08, 2026



Publication list [115 publications up to 08/07/2026]

1. Optical coherence tomography angiography: a window on systemic sclerosis microangiopathy.

Orlandi M, Verdina T, Santoro F, El Alouani M, Gibertini M, Nuara M, **Carobbio A**, Roveta G, Spinella A, De Pinto M, Querques G, Giuggioli D.

Eur J Intern Med. 2026 Jul;149:106819. doi: 10.1016/j.ejim.2026.106819. PMID: 41833472.

2. Distinctive Clinical Features of Portal Hypertension in Children with Portal Vein Thrombosis Following Liver Transplantation.

Sansotta N, Di Giorgio A, Colusso MM, Salvi M, Marra P, Pinelli D, **Carobbio A**, D'Antiga L.

Biomedicines. 2025 Aug 24;13(9):2061. doi: 10.3390/biomedicines13092061. PMID: 41007625.

3. Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients.

Tefferi A, Loscocco GG, Rokach L, Tadmor T, Faldu P, Melamed G, Alapi H, Abdelmagid M, Abdelaziz RM, Yousuf M, Nakhleh M, Pardanani A, Begna KH, Patnaik MM, Szuber N, **Carobbio A**, Barbui T, Reichard KK, He R, Guglielmelli P, Gangat N, Vannucchi AM.

Am J Hematol. 2025 Nov;100(11):2017-2027. doi: 10.1002/ajh.70065. PMID: 40899793.

4. Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.

Barbui T, Stefano V, Rossi E, Ghirardi A, **Carobbio A**, Loscocco GG, Condorelli A, Guglielmelli P.

Am J Hematol. 2025 Mar 10. doi: 10.1002/ajh.27657. Online ahead of print. PMID: 40062566.

4. Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.

Guglielmelli P, Ghirardi A, **Carobbio A**, Masciulli A, Morrone L, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Boldrini V, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larrán A, Andreasson B, Vannucchi AM, Barbui T.

Hemasphere. 2025 Jan 31;9(2):e70072. doi: 10.1002/hem3.70072. PMID: 39897086.

5. Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis.

Barbui T, **Carobbio A**, Ghirardi A, Fenili F, Finazzi MC, Castelli M, Vannucchi AM, Guglielmelli P, Rambaldi A, Gangat N, Tefferi A.

Blood Cancer J. 2024 Nov 6;14(1):195. doi: 10.1038/s41408-024-01176-7. PMID: 39505848.

6. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.

Barbui T, Ghirardi A, **Carobbio A**, De Stefano V, Rambaldi A, Tefferi A, Vannucchi AM.

Blood Cancer J. 2024 Oct 25;14(1):188. doi: 10.1038/s41408-024-01169-6. PMID: 39455571.

7. Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.

Barbui T, **Carobbio A**, Guglielmelli P, Ghirardi A, Fenili F, Loscocco GG, De Stefano V, Ramundo F, Finazzi MC, Rambaldi A, Vannucchi AM.

Br J Haematol. 2024 Dec;205(6):2287-2294. doi: 10.1111/bjh.19813. PMID: 39375955

8. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study.

Ghirardi A, **Carobbio A**, Guglielmelli P, Rambaldi A, De Stefano V, Vannucchi AM, Tefferi A, Barbui T.

Blood Cancer J. 2024 Apr 22;14(1):68. doi: 10.1038/s41408-024-01052-4. PMID: 38649342

9. Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients.

Barbui T, **Carobbio A**.

Blood Cancer J. 2024 Jan 23;14(1):17. doi: 10.1038/s41408-024-00987-y. PMID: 38253717

10. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.

Barbui T, **Carobbio A**, Thiele J, Gangat N, Rumi E, Rambaldi A, Vannucchi AM, Tefferi A; IWG-MRT group.

Blood Cancer J. 2023 Dec 15;13(1):187. doi: 10.1038/s41408-023-00960-1. PMID: 38102114

11. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Barbui T, **Carobbio A**, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM.

Ann Hematol. 2023 Dec 7. doi: 10.1007/s00277-023-05577-9. Online ahead of print. PMID: 38060001

12. Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke?

Barbui T, **Carobbio A**, Vannucchi AM, De Stefano V.

Blood Adv. 2023 Dec 26;7(24):7551-7553. doi: 10.1182/bloodadvances.2023012007. PMID: 37874911

13. A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.

Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardananani A, Hanson CA, Ketterling RP, De Stefano V, **Carobbio A**, Barbui T, Guglielmelli P, Gangat N, Vannucchi AM.

Am J Hematol. 2023 Dec;98(12):1829-1837. doi: 10.1002/ajh.27079. PMID: 37665758

14. Risk factors for intubation in severe bronchiolitis: a useful tool to decide on an early intensive respiratory support.

Colombo J, Gattoni C, **Carobbio A**, Nacoti M, Pelliccioli I, Vedovati S, Bonanomi E.

Minerva Pediatr (Torino). 2023 Oct;75(5):689-696. doi: 10.23736/S0026-4946.20.05574-7. PMID: 32493000

15. Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.

Cuomo M, **Carobbio A**, Aloisi M, Alvisi P, Banzato C, Bosa L, Bramuzzo M, Campanozzi A, Catassi G, D'Antiga L, Di Paola M, Felici E, Fioretti MT, Gatti S, Graziano F, Lega S, Lionetti P, Marseglia A, Martinelli M, Musto F, Sansotta N, Scarallo L, Zuin G, Norsa L.

Inflamm Bowel Dis. 2023 Sep 1;29(9):1380-1389. doi: 10.1093/ibd/izac215. PMID: 36222487

16. Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer

Barbui T, Gavazzi A, Sciatti E, Finazzi MC, Ghirardi A, Carioli G, **Carobbio A**.

Curr Hematol Malig Rep. 2023 Aug;18(4):105-112. doi: 10.1007/s11899-023-00697-5. PMID: 37221411

17. Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach.

Carobbio A, Vannucchi AM, Rumi E, De Stefano V, Rambaldi A, Carli G, Randi ML, Gisslinger H, Passamonti F, Thiele J, Gangat N, Tefferi A, Barbui T.

Blood Cancer J. 2023 Jul 28;13(1):115. doi: 10.1038/s41408-023-00887-7. PMID: 37507408

18. Ropoginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera

Barbui T, Vannucchi AM, De Stefano V, **Carobbio A**, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.

NEJM Evid. 2023 Jun;2(6):EVIDoA2200335. doi: 10.1056/EVIDoA2200335. PMID: 38320126

19. One-year mortality in COVID-19 is associated with patients' comorbidities rather than pneumonia severity.

Novelli L, Raimondi F, Carioli G, **Carobbio A**, Pappacena S, Biza R, Trapasso R, Anelli M, Amoroso M, Allegri C, Malandrino L, Imeri G, Conti C, Beretta M, Gori M, D'Elia E, Senni M, Lorini FL, Rizzi M, Cosentini R, Rambaldi A, Masciulli A, Gavazzi A, Solidoro P, Sironi S, Fagioli S, Barbui T, Marco FD; HPG23 Covid19 Study Group.

Respir Med Res. 2023 Jun;83:100976. doi: 10.1016/j.resmer.2022.100976. PMID: 36473331

20. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.

Barbui T, Ghirardi A, **Carobbio A**, Masciulli A, Carioli G, Rambaldi A, Finazzi MC, Bellini M, Rumi E, Vanni D, Borsani O, Passamonti F, Mora B, Brociner M, Guglielmelli P, Paoli C, Alvarez-Larran A, Triguero A, Garrote M, Pettersson H, Andréasson B, Barosi G, Vannucchi AM.

Blood Cancer J. 2022 Nov 16;12(11):156. doi: 10.1038/s41408-022-00743-0. PMID: 36385103

21. Breakthrough infections in MPN-COVID vaccinated patients.

Barbui T, **Carobbio A**, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidele FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nalecz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM.

Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921

22. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.

Barbui T, **Carobbio A**, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM.
Am J Hematol. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27. PMID: 36111658

23. Adherence of ticagrelor in real world patients with aCute coronary syndrome: The AD-HOC study.

Fiocca L, Rossini R, Carioli G, **Carobbio A**, Piazza I, Collaku E, Giubilato S, Amico F, Molfese M, De Benedictis M, Calabria P, Limbruno U, Valente S, Ferlini M, Spezzano T, Senni M, Gavazzi A.
Int J Cardiol Heart Vasc. 2022 Jul 18;42:101092. doi: 10.1016/j.ijcha.2022.101092. eCollection 2022 Oct. PMID: 35873861

24. Association between cuffed tracheal tube use and reduced ventilator-associated pneumonia and conditions after elective cardiac surgery in infants and young children.

Nacoti M, **Carobbio A**, Finazzi S, Pelliccioli I, Consonni F, Ferrari F, Favarato M, Fazzi F, Bonanomi E.
Minerva Anesthesiol. 2022 Nov;88(11):890-900. doi: 10.23736/S0375-9393.22.16293-0. Epub 2022 Jul 14. PMID: 35833854

25. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment.

Barbui T, **Carobbio A**, De Stefano V.
Res Pract Thromb Haemost. 2022 Feb 7;6(1):e12657. doi: 10.1002/rth2.12657. PMID: 35155976

26. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.

Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, Ramundo F, Rossi E, Kanthi Y, Tefferi A, Barbui T.
Blood Cancer J. 2022 Feb 10;12(2):28. doi: 10.1038/s41408-022-00625-5. PMID: 35145055

27. Second versus first wave of COVID-19 in patients with MPN.

Barbui T, Iurlo A, Masciulli A, **Carobbio A**, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nalęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM.
Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. PMID: 35064223

28. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria.

Magro B, Pinelli D, De Giorgio M, Lucà MG, Ghirardi A, **Carobbio A**, Baronio G, Del Prete L, Nounamo F, Gianatti A, Colledan M, Fagioli S.
Cancers (Basel). 2021 Nov 27;13(23):5976. doi: 10.3390/cancers13235976. PMID: 34885087

29. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.

Guglielmelli P, Ghirardi A, **Carobbio A**, Masciulli A, Maccari C, Mora B, Rumi E, Triguero A, Finazzi MC, Pettersson H, Paoli C, Mannelli F, Vanni D, Rambaldi A, Passamonti F, Alvarez-Larran A, Andreasson B, Vannucchi AM, Barbui T.
Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006. PMID: 34753179

30. Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19.

Gori M, Ghirardi A, D'Elia E, Imeri G, Di Marco F, Gavazzi A, **Carobbio A**, Balestrieri G, Giammarresi A, Trevisan R, Amoroso M, Raimondi F, Novelli L, Magro B, Mangia G, Lorini FL, Fagioli S, Barbui T, Rizzi M, Cosentini R, Sironi S, Senni M.
Eur J Prev Cardiol. 2022 May 5;29(5):e196-e199. doi: 10.1093/eurjpc/zwab143. PMID: 34535993

31. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases.

Gangat N, Guglielmelli P, Betti S, Farrukh F, **Carobbio A**, Barbui T, Vannucchi AM, De Stefano V, Tefferi A.
Am J Hematol. 2021 Dec 1;96(12):1580-1586. doi: 10.1002/ajh.26336. PMID: 34453762

32. Long-term follow-up of recovered MPN patients with COVID-19.

Barbui T, Iurlo A, Masciulli A, **Carobbio A**, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A.

Blood Cancer J. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0. PMID: 34135309

33. The impact of a standardized perioperative management on hospital mortality after the Norwood procedure in a low volume center: results and perspectives.

Ferrari F, Nacoti M, **Carobbio A**, Favarato M, DI Dedda GB, Bonanomi E.

Minerva Pediatr (Torino). 2021 Jun 15. doi: 10.23736/S2724-5276.21.06133-4. Online ahead of print. PMID: 34128601

34. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.

Barbui T, De Stefano V, **Carobbio A**, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marín F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J.

Leukemia. 2021 Oct;35(10):2989-2993. doi: 10.1038/s41375-021-01279-1. PMID: 34012132

35. Response to: Ruxolitinib withdrawal due to the COVID-19.

Barbui T, **Carobbio A**.

Leukemia. 2021 Apr;35(4):1219. doi: 10.1038/s41375-021-01187-4. PMID: 33633312

36. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.

Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, **Carobbio A**, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM.

Blood Cancer J. 2021 Feb 4;11(2):21. doi: 10.1038/s41408-021-00417-3. PMID: 33563901

37. Ropoginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

Barbui T, Vannucchi AM, De Stefano V, Masciulli A, **Carobbio A**, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.

Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. PMID: 33476571

38. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.

Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, **Carobbio A**, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A.

Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. PMID: 33414483

39. A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis.

Carobbio A, Guglielmelli P, Rumi E, Cavalloni C, De Stefano V, Betti S, Rambaldi A, Finazzi MC, Thiele J, Vannucchi AM, Tefferi A, Barbui T.

Blood Cancer J. 2020 Oct 14;10(10):100. doi: 10.1038/s41408-020-00368-1. PMID: 33056979

40. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.

Guglielmelli P, **Carobbio A**, Rumi E, De Stefano V, Mannelli L, Mannelli F, Rotunno G, Coltro G, Betti S, Cavalloni C, Finazzi MC, Thiele J, Cazzola M, Vannucchi AM, Barbui T.

Blood Cancer J. 2020 Feb 25;10(2):21. doi: 10.1038/s41408-020-0289-2. PMID: 32098944

41. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.

Masciulli A, Ferrari A, **Carobbio A**, Ghirardi A, Barbui T.

Blood Adv. 2020 Jan 28;4(2):380-386. doi: 10.1182/bloodadvances.2019001158. PMID: 31985808

42. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study

De Stefano V, Ghirardi A, Masciulli A, **Carobbio A**, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson CIM, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.

Blood. 2020 Jan 30;135(5):381-386. doi: 10.1182/blood.2019002614. PMID: 3186940731869407

43. Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study

Pozzi A, Gori M, Iorio A, Iacovoni A, **Carobbio A**, Cioffi G, De Maria R, Grosu A, Fontana A, Canova PA, Calabrese A, Ferrari P, Parati G, Lorini FL, Senni M, Gavazzi A.

Eur J Prev Cardiol. 2020 Dec;27(19):2326-2329. doi: 10.1177/2047487319896431. PMID: 31847560

44. Second cancers in MPN: Survival analysis from an international study.

Marchetti M, Ghirardi A, Masciulli A, **Carobbio A**, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T.

Am J Hematol. 2020 Mar;95(3):295-301. doi: 10.1002/ajh.25700. PMID: 31816122

45. Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?

Barbui T, **Carobbio A**, Ferrari A.

Blood Adv. 2019 Dec;3(23):3951-3952. doi: 10.1182/bloodadvances.2019001159. PMID: 31805188

46. Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study).

Brucato A, Ferrari A, Tiraboschi M, Zucchi A, Cogliati C, Torzillo D, Dentali F, Tavecchia L, Gessi V, Squizzato A, Moretti S, Permian ET, **Carobbio A**, Pasina L, De Stefano F, Tombetti E, Cumetti D, Tognoni G, Barbui T.

Eur J Intern Med. 2020 Feb;72:60-66. doi: 10.1016/j.ejim.2019.10.016. PMID: 31757579

47. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, **Carobbio A**, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2020 Feb; 95(2):156-166. doi: 10.1002/ajh.25677. PMID: 31721282

48. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T.

Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211. Review. PMID: 31175128

49. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.

Barbui T, Ghirardi A, Masciulli A, **Carobbio A**, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.

Leukemia. 2019 May;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. PMID: 31142846

50. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.

Ferrari A, **Carobbio A**, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, Vannucchi AM, Barbui T.

Haematologica. 2019 May;104(12):2391-2399. doi: 10.3324/haematol.2019.221234. PMID: 31123026

51. Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study.

Gritti P, Zangari R, **Carobbio A**, Zucchi A, Lorini FL, Ferri F, Agostinis C, Lanterna LA, Brembilla C, Foresti C, Barbui T, Biroli F.

World Neurosurg. 2019 Apr;128:e531-e540. doi: 10.1016/j.wneu.2019.04.190. PMID: 31048051

52. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.

De Stefano V, Rossi E, **Carobbio A**, Ghirardi A, Betti S, Finazzi G, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y. PMID: 30420642

53. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, **Carobbio A**, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Corsi B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9. PMID: 29535299

54. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.

Marchetti M, **Carobbio A**, Capitoni E, Barbui T.

Am J Hematol. 2018 May;93(5):698-703. doi: 10.1002/ajh.25049. PMID: 29377227

55. Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.

Ghirardi A, **Carobbio A**, Masciulli A, Barbui T.

Blood Cancer J. 2018 Jan 16;8(1):5. doi: 10.1038/s41408-017-0038-3. No abstract available. PMID: 29335456

56. Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit.

Buoro S, Manenti B, Seghezzi M, Dominoni P, Barbui T, Ghirardi A, **Carobbio A**, Marchesi G, Riva I, Nasi A, Ottomano C, Lippi G.

J Clin Pathol. 2018 Apr;71(4):330-335. doi: 10.1136/jclinpath-2017-204643. PMID: 28824010

57. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, **Carobbio A**, Ghirardi A, Tognoni G.

Am J Hematol. 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. PMID: 28699191

58. Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device.

Iacovoni A, Vittori C, Fontana A, **Carobbio A**, Fino C, D'Elia E, Terzi A, Senni M.

Int J Artif Organs. 2017 Apr 18;0. doi: 10.5301/ijao.5000573. PMID: 28430303

59. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials.

Barbui T, **Carobbio A**, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.

Haematologica. 2017 Mar 2. pii: haematol.2017.165126. doi: 10.3324/haematol.2017.165126. PMID: 28255021

60. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, **Carobbio A**, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z. PMID: 28228104

61. Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Barbui T, Thiele J, Gisslinger H, **Carobbio A**, Vannucchi AM, Tefferi A.

Am J Hematol. 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. PMID: 28196400

62. ACE inhibitors and cyto-reductive therapy in polycythemia vera.

Barbui T, Masciulli A, Ghirardi A, **Carobbio A**.

Blood. 2017 Mar 2;129(9):1226-1227. doi: 10.1182/blood-2016-11-752600. PMID: 28028024

63. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.

Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, **Carobbio A**, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A.

JAMA. 2016 Nov 8;316(18):1906-1912. doi: 10.1001/jama.2016.15826. PMID: 27825009

64. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, **Carobbio A**, Griesshammer M, Barbui T.

Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103. PMID: 27813534

65. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.

Barbui T, Vannucchi AM, **Carobbio A**, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. PMID: 27737508

66. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, **Carobbio A**, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T.

Leukemia. 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. PMID: 27113812

67. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, **Carobbio A**, Thiele J, Passamonti F, Falcone C, Tefferi A. *Blood Cancer J.* 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. PMID: 26617062

68. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

Massi D, Brusa D, Merelli B, Falcone C, Xue G, **Carobbio A**, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M. *Ann Oncol.* 2015 Sep;26(9):1980-7. doi: 10.1093/annonc/mdv255. PMID: 26037795

69. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.

Barbui T, Vannucchi AM, **Carobbio A**, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A. *Am J Hematol.* 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. PMID: 25683038

70. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Finazzi MC, **Carobbio A**, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T. *Leukemia.* 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. PMID: 25482134

71. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.

Barbui T, Thiele J, **Carobbio A**, Vannucchi AM, Tefferi A. *Leukemia.* 2015 Apr;29(4):992-3. doi: 10.1038/leu.2014.328. PMID: 25425199

72. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Barbui T, **Carobbio A**, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A. *Blood.* 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. PMID: 25377561

73. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, **Carobbio A**, Urso C, Mandalà M. *Mod Pathol.* 2015 Apr;28(4):487-97. doi: 10.1038/modpathol.2014.137. PMID: 25341653

74. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

Finazzi G, **Carobbio A**, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, Cazzola M, Passamonti F, Rambaldi A, Barbui T. *Blood.* 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676. PMID: 25323688

75. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.

Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, **Carobbio A**, Rulli E, Deaglio S, Mandalà M. *Ann Oncol.* 2014 Dec;25(12):2433-42. doi: 10.1093/annonc/mdu452. PMID: 25223485

76. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Lussana F, **Carobbio A**, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T. *Br J Haematol.* 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. PMID: 25130523

77. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.

Martinelli I, De Stefano V, **Carobbio A**, Randi ML, Santarossa C, Rambaldi A, Finazzi MC, Cervantes F, Arellano-Rodrigo E, Rupoli S, Canafoglia L, Tieghi A, Facchini L, Betti S, Vannucchi AM, Pieri L, Cacciola R, Cacciola E, Cortezzi A, Iurlo A, Pogliani EM, Elli EM, Spadea A, Barbui T. *Am J Hematol.* 2014 Nov;89(11):E200-5. doi: 10.1002/ajh.23809. PMID: 25042466

78. Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

Barbui T, Thiele J, Kvasnicka HM, **Carobbio A**, Vannucchi AM, Tefferi A. *Leukemia.* 2014 Oct;28(10):2092-4. doi: 10.1038/leu.2014.175. PMID: 24888272

79. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI).

Rizzi M, Ravasio V, **Carobbio A**, Mattucci I, Crapis M, Stellini R, Pasticci MB, Chinello P, Falcone M, Grossi P, Barbaro F, Pan A, Viale P, Durante-Mangoni E; Investigators of the Italian Study on Endocarditis.
BMC Infect Dis. 2014 Apr 29;14:230. doi: 10.1186/1471-2334-14-230. PMID: 24779617

80. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

Barbui T, Thiele J, **Carobbio A**, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A.
Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. PMID: 24535932

81. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, **Carobbio A**, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.
Haematologica. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. PMID: 24389309

82. Masked polycythemia vera diagnosed according to WHO and BCSH classification.

Barbui T, Thiele J, **Carobbio A**, Gisslinger H, Finazzi G, Rumi E, Luigia Randi M, Vannucchi AM, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.
Am J Hematol. 2014 Feb;89(2):199-202. doi: 10.1002/ajh.23617. PMID: 24166817

83. Masked polycythemia vera (mPV): results of an international study.

Barbui T, Thiele J, Gisslinger H, Finazzi G, **Carobbio A**, Rumi E, Luigia Randi M, Betozi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.
Am J Hematol. 2014 Jan;89(1):52-4. doi: 10.1002/ajh.23585. PMID: 23996471

84. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.

Barbui T, **Carobbio A**, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V, Rambaldi A, Vannucchi AM, Barosi G.
Leukemia. 2013 Oct;27(10):2084-6. doi: 10.1038/leu.2013.207. PMID: 23828261

85. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, **Carobbio A**, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T.
Leukemia. 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. PMID: 23739289

86. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.

Ruella M, Salmoiraghi S, Rizzo A, **Carobbio A**, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.
Exp Hematol. 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007. PMID: 23542632

87. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Barbui T, Finazzi G, **Carobbio A**, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A.
Blood. 2012 Dec 20;120(26):5128-33; quiz 5252. doi: 10.1182/blood-2012-07-444067. PMID: 23033268

88. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, **Carobbio A**, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.
Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. PMID: 22740446

89. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

Barbui T, Thiele J, **Carobbio A**, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A.
Blood. 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. PMID: 22700720

90. Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing.

Zambelli M, Andorno E, De Carlis L, Rossi G, Cillo U, De Feo T, **Carobbio A**, Giacomoni A, Bottino G, Colledan M.
Am J Transplant. 2012 Aug;12(8):2198-210. doi: 10.1111/j.1600-6143.2012.04071.x. PMID: 22578214

91. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, **Carobbio A**, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T. *Am J Hematol.* 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. PMID: 22573503

92. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.

Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M, Lambertenghi-Deliliers G, Benedetti F, Bruno B, Corradini P, Alessandrino PE, Iacopino P, Arcese W, Scimè R, Raimondi R, Sica S, Castagna L, Lamparelli T, Oneto R, Lombardini L, Pollichieni S, Algarotti A, **Carobbio A**, Sacchi N, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo, GITMO. *Leukemia.* 2012 Aug;26(8):1779-85. doi: 10.1038/leu.2012.55. PMID: 22377898

93. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Pieri L, Rotunno G, Gisslinger H, Gisslinger B, Müllauer L, Finazzi G, **Carobbio A**, Gianatti A, Ruggeri M, Nichele I, D'Amore E, Rambaldi A, Tefferi A. *Blood.* 2012 Mar 8;119(10):2239-41. doi: 10.1182/blood-2011-11-393819. PMID: 22246040

94. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.

Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. *Am J Hematol.* 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241. PMID: 22237692

95. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

Finazzi G, **Carobbio A**, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T. *Leukemia.* 2012 Apr;26(4):716-9. doi: 10.1038/leu.2011.258. PMID: 21926959

96. ASXL1 mutations in primary and secondary myelofibrosis.

Ricci C, Spinelli O, Salmoiraghi S, Finazzi G, **Carobbio A**, Rambaldi A. *Br J Haematol.* 2012 Feb;156(3):404-7. doi: 10.1111/j.1365-2141.2011.08865.x. PMID: 21923651

97. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, **Carobbio A**, Gianatti A, Gangat N, Hanson CA, Tefferi A. *J Clin Oncol.* 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. PMID: 21747083

98. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Finazzi G, Gangat N, Tefferi A, Barbui T. *Blood.* 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. PMID: 21490340

99. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.

Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, **Carobbio A**, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. *J Clin Oncol.* 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. PMID: 21189387

100. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Barbui T, **Carobbio A**, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, Guglielmelli P, Pancrazzi A, Salmoiraghi S, Zilio P, Ottomano C, Marchioli R, Cuccovillo I, Bottazzi B, Mantovani A, Rambaldi A; AGIMM and IIC Investigators. *Haematologica.* 2011 Feb;96(2):315-8. doi: 10.3324/haematol.2010.031070. PMID: 21173097

101. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.

Rambaldi A, Dellacasa CM, Finazzi G, **Carobbio A**, Ferrari ML, Guglielmelli P, Gattoni E, Salmoiraghi S, Finazzi MC, Di Tollo S, D'Urzo C, Vannucchi AM, Barosi G, Barbui T. *Br J Haematol.* 2010 Aug;150(4):446-55. doi: 10.1111/j.1365-2141.2010.08266.x. PMID: 20560970

102. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.

Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, Rodeghiero F, Delaini F, Rambaldi A, Barbui T. *Blood*. 2010 Aug 19;116(7):1051-5. doi: 10.1182/blood-2010-03-272179. PMID: 20479281

103. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Antonioli E, **Carobbio A**, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, Ponziani V, Bartalucci N, Tozzi L, Bosi A, Rambaldi A, Barbui T, Vannucchi AM.

Haematologica. 2010 Aug;95(8):1435-8. doi: 10.3324/haematol.2009.021444. PMID: 20418246

104. Thrombosis in primary myelofibrosis: incidence and risk factors.

Barbui T, **Carobbio A**, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G.

Blood. 2010 Jan 28;115(4):778-82. doi: 10.1182/blood-2009-08-238956. PMID: 19965680

105. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.

Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, Vannucchi AM, Mappa S, Rossi G, Rossi V, Di Bona E, Paratore S, **Carobbio A**, Rambaldi A, Barbui T, Bassan R.

Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. PMID: 19735261

106. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, Salmoiraghi S, Delaini F, Rambaldi A, Barbui T. *Exp Hematol*. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. PMID: 19559071

107. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Barbui T, **Carobbio A**, Rambaldi A, Finazzi G.

Blood. 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. PMID: 19372254

108. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T.

Blood. 2008 Oct 15;112(8):3135-7. doi: 10.1182/blood-2008-04-153783. PMID: 18587010

109. Leukocytosis and risk stratification assessment in essential thrombocythemia.

Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Finazzi G, Rambaldi A, Barbui T.

J Clin Oncol. 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. PMID: 18443353

110. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, **Carobbio A**, Introna M, Barbui T, Golay J, Rambaldi A.

Leukemia. 2008 Apr;22(4):740-7. PMID: 18079739

111. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.

Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, **Carobbio A**, Micò C, Rambaldi A, Golay J, Introna M.

Bone Marrow Transplant. 2007 Oct;40(8):785-91. PMID: 17680021

112. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Finazzi G, Rambaldi A, Guerini V, **Carobbio A**, Barbui T.

Haematologica. 2007 Jan;92(1):135-6. PMID: 17229651

113. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T.

Blood. 2007 Mar 15;109(6):2310-3. PMID: 17110452

114. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials.

Corrao G, Botteri E, Bagnardi V, Zambon A, **Carobbio A**, Falcone C, Leoni O.

Pharmacoepidemiol Drug Saf. 2005 Jan;14(1):31-40. PMID: 15390219